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Aim: To investigate clinical outcomes in patients with atrial fibrillation exposed to different types of 
anticoagulant drugs within a single institution retrospective registry. 
Patients and Methods: A cohort of 758 consecutive patients with non- valvular atrial fibrillation re-
ceiving anticoagulation therapy after first referral to our institution in a period from 2012 to 2018. We 
analyzed demographic and clinical data, first choice anticoagulation therapy and time of any of the 
following clinical outcomes: death, thromboembolic event, and major bleeding and performed univari-
ate and multivariate analyses. 
Results: There were 434 (57%) patients receiving warfarin, and 178 (23%) and 146 (20%) patients re-
ceiving dabigatran and AntiXa, respectively. There was a statistically significant trend of increase in 
frequency of DOAC use over time (P=0.002). Patients anticoagulated with warfarin were significantly 
older, had lower eGFR and LVEF, had more frequent chronic heart failure, coronary artery disease, per-
manent atrial fibrillation, higher CHA2DS2VASC and higher HAS-BLED scores than DOAC receiving 
patients (P<0.05 for all comparisons). Only 11% of patients on warfarin had acceptable recorded time in 
therapeutic range values. Univariately, there were significantly more events in patients treated with 
warfarin than with DOACs (p<0,001 for all events). After adjusting for age, eGFR, and EFLV time to death 
(HR=5.08, 95% CI (2.23-11.61), P<0.001) and time to thromboembolic event (HR=3.38, 95% CI (1.30-11.12), 
P=0.045) were significantly shorter in warfarin then in DOAC treated patients, whereas time to major 
bleeding (HR=1.01, 95% CI (0.84-2.55), P=0.110) did not differ significantly. 
Conclusion: Patients with higher risk received warfarin more frequently, possibly due to reimburse-
ment issues. Patients receiving warfarin experience significantly higher adjusted risks of thrombo-
sis and death, probably reflecting differences in patients’ characteristics and predetermined risks for 
stroke or other cardiovascular events at baseline. Although the use of DOACS increased over time, 
changes in DOAC availability for all patients should be made to optimize patterns of anticoagulation 
in atrial fibrillation.1
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